August 30, 2024

J&J targets generalised myasthenia gravis landscape with nipocalimab – Pharmaceutical Technology

August 30, 2024

J&J Poised to Challenge Argenx With Myasthenia Gravis Filing for Nipocalimab – BioSpace

August 30, 2024

Merck KGaA doses first subject in Phase III generalised Myasthenia Gravis trial – Clinical Trials Arena

August 29, 2024

Personalized Pathways for Managing Generalized Myasthenia Gravis: The Role of FcRn Antagonism – PRIME® Continuing Medical Education

August 29, 2024

Johnson & Johnson seeks first approval of nipocalimab to treat broadest population living with antibody positive generalized myasthenia gravis – PR Newswire